Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration

Marcello Chimienti, Mario B. Regazzi, Maria Teresa La Rovere, Jorge A. Salerno, Mario Previtali, Vincenzo Montericcio, Renato Rondanelli, Carlo Montemartini

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The aim of this study was to compare the pharmacokinetics and antiarrhythmic activity of dihydroquinidine and quinidine in 14 patients (11 men, 3 women, aged 28 to 67 years) with heart disease and chronic, stable, highfrequency premature ventricular beats (PVB) (>100/hr). A randomized, double-blind, crossover, placebo-controlled protocol was utilized. During Holter monitoring the patients were given either dihydroquinidine or quinidine as the gluconates in an oral solution (600 mg); blood samples were taken 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours later. The patients were then assigned to three successive treatment periods of 7 days each: dihydroquinidine HCl (900 mg/day), quinidine polygalacturonate (1,650 mg/day), or placebo. At the end of each period 24-hour Holter monitoring was carried out and a blood sample was taken for determination of drug concentration. By comparing the area under the curves dihydroquinidine was 59% as available as quinidine; rates of absorption and elimination were similar. Mean peak blood levels of dihydroquinidine and quinidine were 1.06±0.34 and 2.15±0.96 μg/ml, respectively. After dihydroquinidine, eight patients had a positive response (>50% reduction in PVB frequency), while seven patients responded to quinidine. During maintenance treatment both dihydroquinidine (233±330) and quinidine (234±311) reduced the mean PVB frequency per hour compared to placebo (690±569). Nine patients (64%) on dihydroquinidine and eight (57%) on quinidine had >70% decrease in mean PVB frequency per hour. Steady-state peak plasma concentrations of dihydroquinidine and quinidine were 1.10±0.41 and 2.24±1.13 μg/ml, respectively. Dihydroquinidine thus has stronger antiarrhythmic activity than quinidine and so may be used in lower doses; it is effective with plasma concentrations lower than those of quinidine.

Original languageEnglish
Pages (from-to)679-686
Number of pages8
JournalCardiovascular Drugs and Therapy
Volume2
Issue number5
DOIs
Publication statusPublished - Dec 1988

Fingerprint

Quinidine
Ventricular Premature Complexes
Ambulatory Electrocardiography
Placebos
hydroquinidine
Area Under Curve
Heart Diseases
Pharmacokinetics

Keywords

  • antiarrhythmic agents
  • dihydroquinidine
  • Holter monitor ring
  • pharmacokineties
  • quinidine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration. / Chimienti, Marcello; Regazzi, Mario B.; La Rovere, Maria Teresa; Salerno, Jorge A.; Previtali, Mario; Montericcio, Vincenzo; Rondanelli, Renato; Montemartini, Carlo.

In: Cardiovascular Drugs and Therapy, Vol. 2, No. 5, 12.1988, p. 679-686.

Research output: Contribution to journalArticle

Chimienti, Marcello ; Regazzi, Mario B. ; La Rovere, Maria Teresa ; Salerno, Jorge A. ; Previtali, Mario ; Montericcio, Vincenzo ; Rondanelli, Renato ; Montemartini, Carlo. / Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration. In: Cardiovascular Drugs and Therapy. 1988 ; Vol. 2, No. 5. pp. 679-686.
@article{be8e7ebcdadb471f9220a7908980582a,
title = "Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration",
abstract = "The aim of this study was to compare the pharmacokinetics and antiarrhythmic activity of dihydroquinidine and quinidine in 14 patients (11 men, 3 women, aged 28 to 67 years) with heart disease and chronic, stable, highfrequency premature ventricular beats (PVB) (>100/hr). A randomized, double-blind, crossover, placebo-controlled protocol was utilized. During Holter monitoring the patients were given either dihydroquinidine or quinidine as the gluconates in an oral solution (600 mg); blood samples were taken 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours later. The patients were then assigned to three successive treatment periods of 7 days each: dihydroquinidine HCl (900 mg/day), quinidine polygalacturonate (1,650 mg/day), or placebo. At the end of each period 24-hour Holter monitoring was carried out and a blood sample was taken for determination of drug concentration. By comparing the area under the curves dihydroquinidine was 59{\%} as available as quinidine; rates of absorption and elimination were similar. Mean peak blood levels of dihydroquinidine and quinidine were 1.06±0.34 and 2.15±0.96 μg/ml, respectively. After dihydroquinidine, eight patients had a positive response (>50{\%} reduction in PVB frequency), while seven patients responded to quinidine. During maintenance treatment both dihydroquinidine (233±330) and quinidine (234±311) reduced the mean PVB frequency per hour compared to placebo (690±569). Nine patients (64{\%}) on dihydroquinidine and eight (57{\%}) on quinidine had >70{\%} decrease in mean PVB frequency per hour. Steady-state peak plasma concentrations of dihydroquinidine and quinidine were 1.10±0.41 and 2.24±1.13 μg/ml, respectively. Dihydroquinidine thus has stronger antiarrhythmic activity than quinidine and so may be used in lower doses; it is effective with plasma concentrations lower than those of quinidine.",
keywords = "antiarrhythmic agents, dihydroquinidine, Holter monitor ring, pharmacokineties, quinidine",
author = "Marcello Chimienti and Regazzi, {Mario B.} and {La Rovere}, {Maria Teresa} and Salerno, {Jorge A.} and Mario Previtali and Vincenzo Montericcio and Renato Rondanelli and Carlo Montemartini",
year = "1988",
month = "12",
doi = "10.1007/BF00054209",
language = "English",
volume = "2",
pages = "679--686",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "5",

}

TY - JOUR

T1 - Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration

AU - Chimienti, Marcello

AU - Regazzi, Mario B.

AU - La Rovere, Maria Teresa

AU - Salerno, Jorge A.

AU - Previtali, Mario

AU - Montericcio, Vincenzo

AU - Rondanelli, Renato

AU - Montemartini, Carlo

PY - 1988/12

Y1 - 1988/12

N2 - The aim of this study was to compare the pharmacokinetics and antiarrhythmic activity of dihydroquinidine and quinidine in 14 patients (11 men, 3 women, aged 28 to 67 years) with heart disease and chronic, stable, highfrequency premature ventricular beats (PVB) (>100/hr). A randomized, double-blind, crossover, placebo-controlled protocol was utilized. During Holter monitoring the patients were given either dihydroquinidine or quinidine as the gluconates in an oral solution (600 mg); blood samples were taken 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours later. The patients were then assigned to three successive treatment periods of 7 days each: dihydroquinidine HCl (900 mg/day), quinidine polygalacturonate (1,650 mg/day), or placebo. At the end of each period 24-hour Holter monitoring was carried out and a blood sample was taken for determination of drug concentration. By comparing the area under the curves dihydroquinidine was 59% as available as quinidine; rates of absorption and elimination were similar. Mean peak blood levels of dihydroquinidine and quinidine were 1.06±0.34 and 2.15±0.96 μg/ml, respectively. After dihydroquinidine, eight patients had a positive response (>50% reduction in PVB frequency), while seven patients responded to quinidine. During maintenance treatment both dihydroquinidine (233±330) and quinidine (234±311) reduced the mean PVB frequency per hour compared to placebo (690±569). Nine patients (64%) on dihydroquinidine and eight (57%) on quinidine had >70% decrease in mean PVB frequency per hour. Steady-state peak plasma concentrations of dihydroquinidine and quinidine were 1.10±0.41 and 2.24±1.13 μg/ml, respectively. Dihydroquinidine thus has stronger antiarrhythmic activity than quinidine and so may be used in lower doses; it is effective with plasma concentrations lower than those of quinidine.

AB - The aim of this study was to compare the pharmacokinetics and antiarrhythmic activity of dihydroquinidine and quinidine in 14 patients (11 men, 3 women, aged 28 to 67 years) with heart disease and chronic, stable, highfrequency premature ventricular beats (PVB) (>100/hr). A randomized, double-blind, crossover, placebo-controlled protocol was utilized. During Holter monitoring the patients were given either dihydroquinidine or quinidine as the gluconates in an oral solution (600 mg); blood samples were taken 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours later. The patients were then assigned to three successive treatment periods of 7 days each: dihydroquinidine HCl (900 mg/day), quinidine polygalacturonate (1,650 mg/day), or placebo. At the end of each period 24-hour Holter monitoring was carried out and a blood sample was taken for determination of drug concentration. By comparing the area under the curves dihydroquinidine was 59% as available as quinidine; rates of absorption and elimination were similar. Mean peak blood levels of dihydroquinidine and quinidine were 1.06±0.34 and 2.15±0.96 μg/ml, respectively. After dihydroquinidine, eight patients had a positive response (>50% reduction in PVB frequency), while seven patients responded to quinidine. During maintenance treatment both dihydroquinidine (233±330) and quinidine (234±311) reduced the mean PVB frequency per hour compared to placebo (690±569). Nine patients (64%) on dihydroquinidine and eight (57%) on quinidine had >70% decrease in mean PVB frequency per hour. Steady-state peak plasma concentrations of dihydroquinidine and quinidine were 1.10±0.41 and 2.24±1.13 μg/ml, respectively. Dihydroquinidine thus has stronger antiarrhythmic activity than quinidine and so may be used in lower doses; it is effective with plasma concentrations lower than those of quinidine.

KW - antiarrhythmic agents

KW - dihydroquinidine

KW - Holter monitor ring

KW - pharmacokineties

KW - quinidine

UR - http://www.scopus.com/inward/record.url?scp=0024263458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024263458&partnerID=8YFLogxK

U2 - 10.1007/BF00054209

DO - 10.1007/BF00054209

M3 - Article

VL - 2

SP - 679

EP - 686

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 5

ER -